Results 41 to 50 of about 9,195 (133)

Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study

open access: yesPharmacogenomics and Personalized Medicine, 2019
Laith N AL-Eitan1,2, Islam M Al-Dalalah1, Mohamed M Mustafa3, Mansour A Alghamdi4, Afrah K Elshammari5, Wael H Khreisat5, Mohammed N Al-Quasmi6, Hanan A Aljamal1 1Department of Applied Biological Sciences, Jordan University of Science and Technology ...
AL-Eitan LN   +7 more
doaj  

Physiology-based IVIVE predictions of tramadol from in vitro metabolism data [PDF]

open access: yes, 2014
To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and simulation approach (SimcypA (R)).
Allegaert, Karel   +10 more
core   +1 more source

CYTOCHROME P450 3A13 AND ENDOTHELIN JOINTLY MEDIATE DUCTUS ARTERIOSUS CONSTRICTION TO OXYGEN IN MICE [PDF]

open access: yes, 2011
The fetal ductus arteriosus (DA) contracts to oxygen, and this feature, maturing through gestation, is considered important for its closure at birth.
Angeloni D   +11 more
core   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

open access: yesClinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 631-641, August 2025.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana   +8 more
wiley   +1 more source

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate

open access: yesFundamental &Clinical Pharmacology, Volume 39, Issue 4, Page 1-10, August 2025.
ABSTRACT Chronic kidney disease (CKD) affects over 10% of the world's population and is associated with high morbidity and mortality rates. The management of CKD is complex; CKD alters drug pharmacokinetics and pharmacodynamics and further complicates therapeutic strategies regimens.
Sophie Liabeuf   +6 more
wiley   +1 more source

Do Flame Retardants Promote Vitamin D Deficiency? [PDF]

open access: yes, 2014
Vitamin D deficiency in the Unites States has become more prevalent in recent years. Research has shown that environmental chemicals such as flame-retardants induce hepatic enzymes in the cytochrome P450 family such as CYP24 and CYP3A that are important ...
Petteruti, Audrey
core   +2 more sources

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

open access: yesCancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer   +3 more
wiley   +1 more source

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients [PDF]

open access: yes, 2018
Objective: To measure the in vivo variations of CYP3A activity induced by anti-HIV drugs in human immunodeficiency virus (HIV)1-positive patients. Methods: A low oral dose of midazolam (MID) (0.075mg) was given to the patients and the 30-min total 1-OH ...
Baumann, Pierre   +7 more
core  

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: Recent developments and ethnic considerations [PDF]

open access: yes, 2016
Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and pharmacodynamics.
Andrews, L.M. (Louise)   +6 more
core   +3 more sources

Oral administration of a low dose of midazolam (75μg) as an in vivo probe for CYP3A activity [PDF]

open access: yes, 2018
Objective: We investigated whether the oral administration of a low dose (75µg) of midazolam, a CYP3A probe, can be used to measure the in vivo CYP3A activity.
Aubert, Anne-Catherine   +10 more
core  

Home - About - Disclaimer - Privacy